Key facts
- It has raised $1.5M; the latest was Early Stage VC ($1.5M) in Mar 2026.
- Notable investors include Bpifrance, Alsace Business Angels, Conectus, Key Ventures, Matwin — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Albupad
- ·The full record, as it builds
Funding rounds
No funding rounds for Albupad are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Albupad
Developer of albumin-based biomaterials designed for safer and more effective biomedical applications such as drug delivery and tissue engineering. The company develops and commercializes albumin-derived biomaterial technologies that support controlled drug release, biological integration, and improved therapeutic performance for use in pharmaceutical, regenerative medicine, and healthcare product applications, enabling clients for development of safer therapeutic and regenerative treatments using albumin-based biomaterials.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2024
- Employees
- 5
- Website
- albupad.fr/
- Ownership
- Privately Held (backing)
Albupad doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Albupad shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Albupad in its N-PORT filings yet. We sweep new filings monthly.